3-(4-fluoro-3-nitrophenyl)pyridine | 924264-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(4-fluoro-3-nitrophenyl)pyridine
• CAS: 924264-19-7
• 化学式: C₁₁H₇FN₂O₂
• 分子量: 218.187
• InChiKey: UMDHAJNCWPMODX-UHFFFAOYSA-N

物化性质

• 沸点：
  370.4±32.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-fluoro-3-nitrophenyl)pyridine 在 盐酸 、 tin(ll) chloride 作用下， 生成 2-fluoro-5-(3-pyridyl)aniline
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c
• 作为产物：
  描述：

  4-溴-1-氟-2-硝基苯 、 3-吡啶硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 3-(4-fluoro-3-nitrophenyl)pyridine
  参考文献：
  名称：

  AlCl3 介导的 CHF2 转移和二氟甲氧基官能化邻苯二胺的环缩合获得 N-取代苯并咪唑

  摘要：

  在此，我们首次报道了不含过渡金属的受挫路易斯对 (FLP) 催化 CHF 2基团从氧原子迁移到相邻的氮原子，从而在室温下合成了具有优异性能的 N-取代苯并咪唑。产率、广泛的官能团耐受性和较短的反应时间。在 AlCl 3存在下，连接氧的二氟甲烷作为 C1 源在合成 N 取代苯并咪唑的过程中通过裂解一个 C-O 键和两个 C-F 键，导致形成两个新的 C-N 键。

  DOI：

  10.1021/acs.orglett.2c02231

文献信息

• Benzimidazoles useful as inhibitors of protein kinases
  申请人：Binch Hayley

  公开号：US20070099920A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds useful as inhibitors of Aurora, FLT-3, or PDK1 protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the invention.

  本发明涉及作为Aurora、FLT-3或PDK1蛋白激酶抑制剂的化合物。该发明还提供包含这些化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或障碍的方法。该发明还提供了制备本发明化合物的方法。
• 1-pyrimidinyl- or 1-pyridinyl-2-amino benzimidazole derivatives and related compounds as inhibitors of protein kinases for the treatment of cancer
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP2336122A1

  公开（公告）日：2011-06-22

  The present invention relates to compounds useful as inhibitors of Aurora, FLT-3, or PDK1 protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the invention.

  本发明涉及可用作 Aurora、FLT-3 或 PDK1 蛋白激酶抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病、病症或紊乱的方法。本发明还提供了制备本发明化合物的工艺。
• BENZIMIDAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1937667B1

  公开（公告）日：2010-10-13
• 1-PYRIMIDINYL- OR 1-PYRIDINYL-2-AMINO BENZIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES FOR THE TREATMENT OF CANCER
  申请人：Vertex Pharmaceuticals Inc.

  公开号：EP2336122B1

  公开（公告）日：2014-05-14
• US8076343B2
  申请人：——

  公开号：US8076343B2

  公开（公告）日：2011-12-13